Some studies have linked lithium in drinking water with lower dementia rates, while others have not. Laboratory findings have added new reasons to investigate. The question now is whether those clues can translate into a meaningful benefit in people, and which form of lithium would matter.
Can lithium prevent or reverse Alzheimer's disease?
No prevention or reversal claim is established in humans. What exists is a body of observational research associating higher trace-lithium exposure with lower dementia rates, plus mechanistic and animal work suggesting biological plausibility. Association is not causation, the largest dataset shows a non-linear pattern, at least one individual-level cohort found no benefit, and the 2026 randomized lithium carbonate trial did not meet its primary outcomes. No public-health body recommends lithium to prevent dementia, and "reverse" is not supported by human data.
What did the 2025 lithium-deficiency study show?
Aron and colleagues examined human brain tissue and tested lithium depletion and replacement in mice. The study proposed that amyloid plaques, deposits of protein associated with Alzheimer’s, can bind and trap lithium. The authors used lithium orotate in the mouse experiments because it showed reduced amyloid binding in their experiments.
The work connected changes in lithium availability with several disease-related measurements in the models. That gives researchers a hypothesis to test in people; it does not establish a human deficiency diagnosis or treatment. Read the 2025 study.
Is it actually proven in humans (clinical trials)?
A 2026 randomized trial tested lithium carbonate in 80 older adults with mild cognitive impairment over two years. It did not meet its prespecified primary outcome thresholds. Earlier small trials reported encouraging findings, so the human evidence is mixed. The carbonate trial did not directly test orotate, but its result is not evidence that orotate works or that amyloid binding explains the outcome. Read the trial; compare the human studies.
Earlier, smaller, more encouraging signals predate that trial. A placebo-controlled trial in amnestic mild cognitive impairment reported slowed cognitive and functional decline and attenuated tau hyperphosphorylation with lithium (reviewed in Forlenza and colleagues, 2012, Drugs & Aging; DOI), and a small randomized study reported that a 300 µg/day microdose stabilized cognition over 15 months in Alzheimer's patients (Nunes and colleagues, 2013, Current Alzheimer Research; DOI). These were small, early-stage trials, encouraging but not definitive, and lithium is not approved for dementia. A fuller, form-aware studies database is maintained on the evidence page.
What do human population studies show about lithium and dementia?
The human population signal comes mostly from ecological studies comparing regional drinking-water lithium with regional dementia rates. The findings lean protective at higher exposures but are non-linear and not unanimous.
| Study | Year | Region | Design | Sample | Finding |
|---|---|---|---|---|---|
| Kessing and colleagues | 2017 | Denmark | Ecological nested case-control | 73,731 cases / 733,653 controls | Non-linear: protective above 15 µg/L (IRR 0.83); higher risk in a 5.1–10 µg/L band (IRR 1.22) |
| Fajardo and colleagues | 2017 | Texas, USA | Ecological (county) | County-level | Inverse association for Alzheimer's above roughly 30 µg/L |
| Parker and colleagues | 2018 | USA | Ecological (claims) | Claims data | Crude inverse association vanished after adjustment; small counts |
| Muronaga and colleagues | 2022 | Japan | Ecological | 808 cities/wards (~91% of population) | Inverse association, women only |
| Duthie and colleagues | 2023 | Scotland | Cohort (individual) | ~37,000 | Null overall; paradoxical higher risk in women; exposure very low (<2 µg/L) |
A 2024 review described an association between trace lithium and dementia outcomes across several studies. The underlying designs and exposure estimates differ. It does not establish a beneficial water concentration or a minimum amount a person needs. Read the review.
The dose-plateau and the non-linear picture
The Danish study did not find a simple “more lithium, less dementia” relationship. Different exposure groups had different associations. This is another reason not to turn population data into a target water level or supplement dose. Compare the study findings.
Lithium orotate versus lithium carbonate for the brain
People researching lithium for cognition often encounter lithium orotate sold as a low-dose "brain" supplement. The two forms differ enormously in dose, regulation, and evidence.
| Attribute | Lithium orotate (supplement) | Lithium carbonate (prescription) |
|---|---|---|
| Amount reported | A few milligrams per dose (varies by product) | Check the elemental amount separately from the prescription compound weight |
| Regulatory status | Dietary supplement | FDA-approved medication |
| Monitoring | Not formally established | Routine blood-level, kidney, thyroid monitoring |
| Dementia evidence | No human dementia trials establishing benefit | Studied in psychiatry, not approved for dementia |
Whether lithium orotate behaves differently in the brain than other lithium salts is a genuinely open question. There are promising early reasons it might: the 2025 mouse work used orotate specifically because it showed reduced amyloid binding, and orotate has long been proposed to enter cells or cross into the brain more readily. But this is not proven in humans, the human data are extremely early, and some researchers argue on chemistry grounds that orotate likely dissociates to ordinary lithium ions after ingestion, with pharmacokinetics comparable to carbonate (Hajek and colleagues, 2026; DOI). The honest summary: biologically interesting, mechanistically plausible, clinically unproven. A fuller form comparison lives on Lithium orotate vs carbonate.
How much lithium for brain health?
There is no established dose of lithium for brain health or dementia prevention in the general public. Population associations are based on ambient water concentrations (micrograms per liter), not on any tested supplement regimen, and the dose-response appears non-linear. No preventive dose has been validated in people. Any use of lithium for cognitive purposes is unproven and, in supplement or prescription form, should involve a clinician.
Limitations and safety
Population studies can identify patterns, but differences in exposure estimates and regional factors make them difficult to translate into personal advice. Findings include non-linear associations and null results; the Scottish study does not establish that concentrations below 2 µg/L are biologically irrelevant. Small human trials are mixed, and the 2026 carbonate trial did not meet its primary outcome thresholds. Lithium is not established for dementia prevention. Prescription lithium requires medical monitoring, and long-term safety of low-dose supplements remains insufficiently characterized.
Frequently asked questions
Does lithium prevent dementia?
No prevention claim is established. Multiple observational studies associate higher trace-lithium exposure in drinking water with lower dementia rates, but the evidence is ecological, non-linear, and includes null results. Causation is unproven, the 2026 randomized lithium carbonate trial did not meet its primary outcomes, and no health authority recommends lithium for dementia prevention.
Can lithium reverse Alzheimer's disease?
Human data do not support reversing Alzheimer's with lithium. A 2025 Nature study reported lithium depletion in the Alzheimer's brain and that restoring lithium with lithium orotate prevented pathology in mice, but animal findings establish plausibility, not human treatment. The 2026 randomized lithium carbonate trial of low-dose lithium in mild cognitive impairment did not meet its primary outcomes.
Is lithium orotate good for memory?
There are no human trials establishing that lithium orotate improves memory or prevents dementia. Whether it behaves differently in the brain than other lithium salts is an open question: the 2025 mouse work used orotate because it showed reduced amyloid binding, but this is unproven in humans, the data are very early, and some researchers argue it likely dissociates to ordinary lithium ions after ingestion. It is a low-dose dietary supplement, not a medication, and its benefits and long-term safety are not established. Discuss any use with a clinician.
What dose of lithium helps the brain?
No brain-health dose is established for the general public. Population associations are based on ambient water concentrations in micrograms per liter, not on tested supplement doses, and the dose-response appears non-linear rather than "more is better."
Why do some studies find no benefit?
A 2026 randomized trial tested lithium carbonate in 80 older adults with mild cognitive impairment over two years. It did not meet its prespecified primary outcome thresholds. Earlier small trials reported encouraging findings, so the human evidence is mixed. The carbonate trial did not directly test orotate, but its result is not evidence that orotate works or that amyloid binding explains the outcome. Read the trial; compare the human studies.
Is low-dose lithium safe to take for prevention?
The long-term safety of low-dose supplemental lithium is not well studied, and there is no proven preventive benefit. Prescription lithium has serious, monitored risks. Decisions about any lithium use should involve a medical professional.
Related pages
- Lithium and the brain: the complete guide
- How lithium works in the brain
- Lithium orotate vs carbonate: forms, dosing, safety
- Lithium in drinking water
- DHA and companion nutrients
- What the research actually says (evidence)
References
- Aron, Ngian, Qiu et al. (2025). Lithium deficiency and the onset of Alzheimer’s disease. Nature.
- Bush (2025). Does lithium deficiency contribute to Alzheimer’s disease?. Nature.
- Forlenza, de Paula, Machado-Vieira et al. (2012). Does Lithium Prevent Alzheimerʼs Disease?. Drugs & Aging.
- Fraiha-Pegado, de Paula, Alotaibi et al. (2024). Trace lithium levels in drinking water and risk of dementia: a systematic review. International Journal of Bipolar Disorders.
- Gildengers, Ibrahim, Anderson et al. (2026). Low-Dose Lithium for Mild Cognitive Impairment. JAMA Neurology.
- Hajek, Munthe, Licht (2026). Lithium orotate: distinct compound or simply Li + after administration?. The British Journal of Psychiatry.
- Kessing, Gerds, Knudsen et al. (2017). Association of Lithium in Drinking Water With the Incidence of Dementia. JAMA Psychiatry.
- Moore, Bose, Henter et al. (2026). The 25-Year Evolution of Lithium as a Disease-Modifying Agent in Dementia. JAMA Psychiatry.
- Andrade Nunes, Araujo Viel, Sousa Buck (2013). Microdose Lithium Treatment Stabilized Cognitive Impairment in Patients with Alzheimer’s Disease. Current Alzheimer Research.
